Janssen Pharmaceuticals, Inc.
GPTKB entity
Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
gptkb:Taris_Biomedical
gptkb:Actelion gptkb:Centocor |
| gptkbp:awards |
various industry awards
|
| gptkbp:clinical_trial |
collaborative studies
patient-centered research biomarker studies real-world evidence studies drug development programs multiple ongoing studies |
| gptkbp:founded |
1953
|
| gptkbp:founder |
gptkb:Paul_Janssen
|
| gptkbp:global_presence |
over 150 countries
|
| gptkbp:headquarters |
gptkb:Beerse,_Belgium
|
| https://www.w3.org/2000/01/rdf-schema#label |
Janssen Pharmaceuticals, Inc.
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:market_position |
strong presence in cardiovascular
strong presence in immunology strong presence in infectious diseases strong presence in neuroscience strong presence in oncology |
| gptkbp:number_of_employees |
over 40,000
|
| gptkbp:parent_company |
gptkb:Johnson_&_Johnson
|
| gptkbp:partnerships |
government agencies
biotechnology companies various academic institutions |
| gptkbp:philanthropy |
research funding
healthcare initiatives community support programs |
| gptkbp:products |
antibiotics
antipsychotics oncology drugs immunology drugs |
| gptkbp:region |
gptkb:Africa
gptkb:Europe gptkb:Asia gptkb:Latin_America gptkb:North_America |
| gptkbp:regulatory_compliance |
FDA approvals
EMA approvals other international approvals |
| gptkbp:research_focus |
oncology
neuroscience infectious diseases immunology cardiovascular |
| gptkbp:subsidiary |
gptkb:Johnson_&_Johnson
|
| gptkbp:sustainability_initiatives |
water conservation efforts
supply chain sustainability waste reduction efforts energy efficiency projects environmental responsibility programs |
| gptkbp:website |
www.janssen.com
|
| gptkbp:bfsParent |
gptkb:Janssen_Pharmaceutica
|
| gptkbp:bfsLayer |
5
|